All Antabio programs address World Health Organization critical priority pathogens and are eligible for streamlined development. Its lead program, MBLI, which is expected to enter the clinic in 2020, addresses a critical global threat that is already highly prevalent in Asia-Pacific.

The French company is targeting strategic partnerships in Asia-Pacific to maximize its peak sales potential.